Just, Johannes Maximilian http://orcid.org/0000-0003-0866-5480
Bingener, Linda
Bleckwenn, Markus
Schnakenberg, Rieke
Weckbecker, Klaus
Article History
Received: 3 July 2017
Accepted: 25 May 2018
First Online: 20 June 2018
Ethics approval and consent to participate
: The study was carried out under the declaration of Helsinki. It received ethical approval by the Ethics Committee of the Medical Faculty of the University of Bonn (No. 243/16). Participants received oral and written information on the study as well as the questionnaire. They were then given the option to put an empty or filled out anonymous questionnaire in a sealed box which was later handed over to the researchers. This procedure was used to give patients the opportunity of non-participation without being revealed. The return of a completed questionnaire was then interpreted as informed consent obtained from participants.
: Indivior Germany™ gave us consent to use their translation of the COMM® thereby saving us the effort of high-quality translation. Klaus Weckbecker was a member of the advisory board of Indivior Germany™, manufacturer of Buprenorphine, a treatment option for opioid addiction. Additionally he received fees for lectures on addiction medicine from the same company. He has terminated these activities in 2015.All other authors declare no conflict of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.